Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

2006 due to competitive pressures in the Company's generic segment, where revenues decreased 18.2% to $136.0 million, as sales declines in fluticasone and amoxicillin were somewhat tempered by gains from the 2007 launch of additional strengths of metoprolol succinate ER and propranolol HCl ER. Strativa revenues increased 10.7% from the prior year to $19.1 million driven by increased sales of Megace(R) ES, which grew by 19.3%.

The Company's fourth quarter 2007 gross margin of $57.8 million decreased 1.9% as lower Generic segment margin was tempered by increased gross margin from the Strativa branded division on increased sales of Megace(R) ES.

R&D expense decreased 10.5% from the fourth quarter 2006 to $16.5 million, driven by the non-recurrence of Difimicin (Par 101) development costs and lower overall development costs related to generic R&D projects.

SG&A expense for the fourth quarter of 2007 increased 1.6% to $37.8 million, driven by higher other compensation costs, including costs associated with the tender offer to repurchase certain unvested stock options, and increased legal costs, somewhat tempered by lower severance related expense.

Restatement of 2005 and 2006 Discontinued Operations and Net Loss

In preparing its consolidated financial statements for year ended December 31, 2007, the Company identified accounting errors related to its discontinued operations reported in the Company's 2006 and 2005 financial information contained in its Annual Report on Form 10-K for the year ended December 31, 2006 and filed on September 6, 2007. Management determined that the benefit for income taxes on discontinued operations for the year ended December 31, 2005 was overstated because the Company did not properly determine the income tax benefits from discontinued operations, which resulted in the understatement of the Company's net loss for 2005 by $19 million. Management also determined that the 2006 provision for income taxes from d
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... An article in Fortune on Monday, March ... to organizations that deal with PCI (Payment Card Information); ... security, is worsening . Using numbers from Verizon’s ... category out of the twelve measured improved, barring one ... craziness that has gone on in the retail industry ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., has ... The Who and the Doors played together at the Singer ... to Hawley, “The Who toured the United States heavily from ... Perhaps the most famous Who poster was a poster created ... on August 2, 1968 at the Singer Bowl in Flushing, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... NEW YORK, July 13, 2010 The decision regarding ... carcinoma in-situ (DCIS) has long been an area of ... the mortality rates for DCIS remain low, the risk ... treatments following surgery include radiation therapy and hormone treatment. ...
... Science Associates, the company that manages the U.S. ... Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have ... second-generation technology for designing synthetic peptides that are ... are designed to communicate growth signals to cells ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, July ... knew more than a decade ago that the blockbuster diabetes ... up the information, according to a report published Tuesday in ... trial pitting Avandia against its competitor, Actos, the drug company, ...
... a brooding, complicated people, and ethnographers have confirmed that ... more than Westerners do. But a new University of ... brood, they are less likely than Americans to feel ... on one,s negative feelings tends to impair well-being, but ...
... (July 13, 2010) With current public health threats ... innovations that better predict disease outbreaks have vast potential ... in advance of print on July 6 in ... their vision for the future of disease surveillance, detailing ...
... , TUESDAY, July 13 (HealthDay News) -- Children and ... involuntary tics through self-hypnosis, a small new study suggests. ... too preliminary to indicate whether the strategy actually works. ... the Journal of Developmental & Behavioral Pediatrics , researchers ...
Cached Medicine News:Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Brookhaven Lab and BioSET Inc. patent improved growth factor technology 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3Health News:Brooding Russians: Less distressed than Americans 2Health News:Researchers envision better disease surveillance to improve public health 2Health News:Can Self-Hypnosis Help Tourette Patients Control Tics? 2
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... OAK, Mich. , March 26, 2015 ... have performed the Midwest,s first commercial implant of ... Administration for patients with non-valvular atrial fibrillation. The Watchman ... long-term use of blood-thinning warfarin medication to reduce the ... most common heart rhythm disorder affecting more than 5 ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... May 24, 2011 The National Community ... Competition and Consumer Choice Act of 2011 , ... the pharmacy of their choice, eliminate needless pharmaceutical ... abusive pharmacy audits. (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ...
... May 24, 2011 A coalition of advocacy groups and ... for the District of Columbia Circuit to compel the Obama ... marijuana rescheduled under the provisions of the Controlled Substances Act ... would enable states with medical marijuana laws to expedite efforts ...
Cached Medicine Technology:Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 2Community Pharmacists Endorse Bipartisan Pharmacy Competition and Consumer Choice Act 3Federal Court Asked to Compel Decision in Marijuana Scheduling Action 2Federal Court Asked to Compel Decision in Marijuana Scheduling Action 3
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Refkeratometer...
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
Medicine Products: